XRP price stock: Token slips near $2.12 as Senate pauses crypto bill, Ripple cites Luxembourg nod
15 January 2026
1 min read

XRP price stock: Token slips near $2.12 as Senate pauses crypto bill, Ripple cites Luxembourg nod

New York, Jan 15, 2026, 10:11 ET — Regular session

  • XRP slipped to around $2.12 following a retreat from its recent peak.
  • A Senate committee delayed debate on a crypto market-structure bill following objections from Coinbase.
  • As Ripple expands further into Europe, it highlighted a preliminary licence from Luxembourg.

XRP dropped roughly 3% to near $2.12 on Thursday, retreating from a high of $2.17 recorded in the previous 24 hours. (CoinDesk)

The dip follows a setback in Washington’s push to regulate crypto. The Senate Banking Committee postponed a scheduled debate on draft legislation aimed at creating a regulatory framework for digital assets after Coinbase CEO Brian Armstrong voiced opposition to the bill as it stands. “We’d rather have no bill than a bad bill,” Armstrong said. Chairman Tim Scott indicated negotiations are ongoing. (Reuters)

Scott’s committee planned to hold an executive session Thursday to review H.R.3633, the Digital Asset Market Clarity Act of 2025. However, the committee’s hearing page now shows the session as postponed. (Senate)

Ripple, known for its XRP token, pushed licensing news on Wednesday, revealing it had won preliminary approval for an Electronic Money Institution (EMI) licence from Luxembourg’s financial watchdog, the CSSF. This follows last week’s nod from U.K. regulators. “The EU was amongst the first major jurisdictions to introduce comprehensive digital assets regulation,” said Ripple President Monica Long. Cassie Craddock, Ripple’s managing director for UK & Europe, described Luxembourg as “a premier hub for financial innovation.” (Ripple)

An EMI licence acts as a regulatory green light, allowing payments companies to issue electronic money and operate payment services under supervision. Ripple is banking on this as it pushes its cross-border payments offering.

Bitcoin held steady near $95,500 as ether lingered close to $3,329. XRP slipped roughly 1.8%, with a number of other major tokens also drifting lower, according to data from Investing.com. (Investing)

The risks, however, are clear. A drawn-out battle over the Senate bill—or tweaks that alter stablecoin rules, like capping “rewards”—could leave the sector in regulatory limbo. XRP often moves with overall market risk appetite, even when news hits specific to the company.

Traders are eyeing a fresh date for the Senate markup and whether Coinbase will rejoin talks. Crypto desks sensitive to macro moves are also focused on the Federal Reserve’s policy meeting set for Jan. 27-28, with the decision expected on Jan. 28. (Federalreserve)

Stock Market Today

  • Medical stocks set to beat earnings as ESP filter flags Gilead, Tenet
    January 15, 2026, 10:43 AM EST. Wall Street watches quarterly results, with earnings surprises shaping near-term moves. The tool at center is the Earnings ESP-the Expected Surprise Prediction-which compares the Most Accurate Estimate with the Zacks Consensus Estimate to gauge likely surprises. A positive ESP paired with a favorable rank has historically yielded upside surprises 70% of the time and 28.3% annual returns, Zacks says. About 60% of names sit at #3 (Hold); stronger ranks at #2 (Buy) and #1 (Strong Buy) tend to outperform. In medical stocks, Gilead Sciences (GILD) sits #3 (Hold) 27 days from its next report on Aug. 8, 2024, with a Most Accurate Estimate of $1.63 vs consensus $1.58, for an ESP of +2.76%. Tenet Healthcare (THC) is another qualifying name, rated #2 Buy, with earnings due July 24, 2024, and a Most Accurate Estimate of $1.97 and an ESP of +7.26%.
Ford stock ticks up as USMCA fight flares again — what investors watch next
Previous Story

Ford stock ticks up as USMCA fight flares again — what investors watch next

Go toTop